文献速递糖尿病

从24-28周妊娠开始治疗的早期与晚期妊娠期糖尿病围产期结局:TOBOGM二次分析

Perinatal Outcomes in Early and Late Gestational Diabetes Mellitus After Treatment From 24-28 Weeks' Gestation: A TOBOGM Secondary Analysis.
PubMed 文献 · Diabetes Care · 2024-01-01

该研究为随机对照试验的二次分析,比较早期GDM(20周前诊断但24-28周才治疗)、晚期GDM(仅24-28周出现)与血糖正常对照的围产期结局。早期GDM复合结局风险升高(OR 1.59,95%CI 1.18-2.12),晚期GDM未升高(OR 1.19,95%CI 0.94-1.50)。结论提示早期GDM即使从24-28周治疗,不良围产期结局仍增加,建议更早、更积极治疗。

要点

  • 早期GDM复合围产期结局风险升高(OR 1.59,95%CI 1.18-2.12),晚期GDM未升高(OR 1.19,95%CI 0.94-1.50)。
  • 早期GDM组引产率、出生体重百分位、早产率和新生儿黄疸率均高于对照组,晚期GDM组未高于对照组。
  • 早期GDM组对胰岛素和/或二甲双胍的需求最大。

核心结论

  • 早期GDM即使从24-28周妊娠开始治疗,不良围产期结局仍增加,提示需要更早、更积极地开始治疗,以减少早孕期更严重母体高血糖暴露的影响。

研究设计与样本

  • 这是随机对照治疗试验的二次分析,在具有危险因素的女性中研究早期(<20周妊娠)GDM,GDM根据世界卫生组织2013标准定义。
  • 接受早期GDM治疗的女性被排除;若24-28周妊娠时仍存在GDM则进行治疗。
  • 比较组包括早期GDM组(n=254)、晚期GDM组(n=467)和24-28周妊娠时血糖正常的对照参与者(n=2,339)。
  • 比较时对年龄、种族、BMI、研究中心、吸烟、初产和教育程度进行了校正。

主要发现

  • 早期GDM组(n=254)和晚期GDM组(n=467)的妊娠持续时间均短于对照参与者(n=2,339)。
  • 晚期GDM组BMI最低。
  • 复合结局在早期GDM组升高(OR 1.59,95%CI 1.18-2.12),但在晚期GDM组未升高(OR 1.19,95%CI 0.94-1.50)。
  • 两个GDM组的引产率均高于对照参与者。
  • 与对照参与者相比,早期GDM组的出生体重百分位更高、早产率更高、新生儿黄疸率更高,而晚期GDM组未出现这些升高。

关键数值与推荐

  • 主要结局为复合结局:37周妊娠前出生、出生体重≥4,500 g、产伤、新生儿呼吸窘迫、光疗、死产/新生儿死亡和肩难产。
  • 早期GDM定义为20周妊娠前诊断,但若GDM仍存在则直到24-28周妊娠才治疗;晚期GDM定义为仅24-28周妊娠时存在。
  • GDM根据世界卫生组织2013标准定义。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In most gestational diabetes mellitus (GDM) studies, cohorts have included women combined into study populations without regard to whether hyperglycemia was present earlier in pregnancy. In this study we sought to compare perinatal outcomes between groups: women with early GDM (EGDM group: diagnosis before 20 weeks' gestation but no treatment until 24-28 weeks' gestation if GDM still present), with late GDM (LGDM group: present only at 24-28 weeks' gestation), and with normoglycemia at 24-28 weeks' gestation (control participants). RESEARCH DESIGN AND METHODS: This is a secondary analysis of a randomized controlled treatment trial where we studied, among women with risk factors, early (<20 weeks' gestation) GDM defined according to World Health Organization 2013 criteria. Those receiving early treatment for GDM treatment were excluded. GDM was treated if present at 24-28 weeks' gestation. The primary outcome was a composite of birth before 37 weeks' gestation, birth weight ≥4,500 g, birth trauma, neonatal respiratory distress, phototherapy, stillbirth/neonatal death, and shoulder dystocia. Comparisons included adjustment for age, ethnicity, BMI, site, smoking, primigravity, and education. RESULTS: Women with EGDM (n = 254) and LGDM (n = 467) had shorter pregnancy duration than control participants (n = 2,339). BMI was lowest with LGDM. The composite was increased with EGDM (odds ratio [OR] 1.59, 95% CI 1.18-2.12) but not LGDM (OR 1.19, 95% CI 0.94-1.50). Induction of labor was higher in both GDM groups. In comparisons with control participants there were higher birth centile, higher preterm birth rate, and higher rate of neonatal jaundice for the EGDM group (but not the LGDM group). The greatest need for insulin and/or metformin was with EGDM. CONCLUSIONS: Adverse perinatal outcomes were increased with EGDM despite treatment from 24-28 weeks' gestation, suggesting the need to initiate treatment early, and more aggressively, to reduce the effects of exposure to the more severe maternal hyperglycemia from early pregnancy.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Simmons D, Immanuel J, Hague WM, et al. Perinatal Outcomes in Early and Late Gestational Diabetes Mellitus After Treatment From 24-28 Weeks' Gestation: A TOBOGM Secondary Analysis. Diabetes Care. 2024. PMID: 38421672. doi:10.2337/dc23-1667

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。